23andMe CEO 'Surprised and Disappointed' by Mass Board Resignation
Wojcicki's statement comes after seven board members resigned in protest of the company's plans to develop drugs.
23andMe CEO Anne Wojcicki expressed surprise and disappointment at the mass resignation of seven board members who objected to the company's plans to develop drugs. In a statement, Wojcicki said she was "surprised and disappointed" by the resignations and that she believed the company's plans to develop drugs were "in the best interests of our customers and shareholders."
The board members who resigned cited concerns about the company's lack of experience in drug development and the potential for conflicts of interest, as 23andMe sells genetic testing kits directly to consumers.
The company's plans to develop drugs have been met with criticism from some experts, who argue that the company lacks the necessary experience and expertise to safely develop and market drugs. Others have raised concerns about the potential for conflicts of interest, as 23andMe sells genetic testing kits directly to consumers.
The mass resignation of board members is a significant setback for 23andMe, which is already facing a number of challenges. The company has been criticized for its handling of customer data, and it is also facing lawsuits from consumers who allege that the company's genetic testing kits are inaccurate.
Komentar